Head-To-Head Contrast: Purple Biotech (NASDAQ:PPBT) & Tiziana Life Sciences (NASDAQ:TLSA)

Purple Biotech (NASDAQ:PPBT) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Risk and Volatility

Purple Biotech has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Valuation and Earnings

This table compares Purple Biotech and Tiziana Life Sciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$19.88 million	($0.81)	-6.67
Tiziana Life Sciences	N/A	N/A	-$17.69 million	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Purple Biotech and Tiziana Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	0	0	1	0	3.00
Tiziana Life Sciences	0	0	0	0	N/A

Purple Biotech currently has a consensus target price of $10.00, suggesting a potential upside of 85.19%. Given Purple Biotech’s higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Tiziana Life Sciences.

Profitability

This table compares Purple Biotech and Tiziana Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-59.58%	-48.06%
Tiziana Life Sciences	N/A	N/A	N/A

Institutional & Insider Ownership

9.6% of Purple Biotech shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.